Eyedeal’s new generation of intraocular lenses debuted at the12th CIMDR

International Conference on Medical Device Supervision and Administration

From September 24 to 26, the 12th International Conference on Medical Device Supervision and Administration (CIMDR) was held in Wuhan, Hubei Province. Focusing on the theme of Implementing the New Regulations and Promoting the New Development of Regulatory Science, the meeting invited the heads of the Medical Device Registration Department, Medical Device Supervision Department, and Device Review Center of the State Food and Drug Administration to comprehensively analyze China’s medical device regulatory regulations, detail the latest progress in China’s medical device review and approval system reform, traceability system construction, and industrial development. As the world’s largest professional conference on medical device regulations, this conference brings together the world’s most cutting-edge medical device products and many pharmaceutical companies.

The picture shows Guo Guangxu, founder, chairman and CEO of Xi’an Eyedeal Medical Technology Co., Ltd., introduce the research and development of the world’s new generation of intraocular lenses to the leadership of the State Food and Drug Administration.

Xi’an Eyedeal Medical Technology Co., Ltd., which was invited to attend this conference, launched the world’s latest generation of intraocular lens product Eyedeal® series, appeared at the exhibition site, and cooperated with Johnson & Johnson, GE, Boston Scientific, Medtronic, Alcon and Baxter. The products of other multinational companies were displayed on the same stage, which attracted widespread attention from industry professionals.

The Eyedeal® series of intraocular lenses are developed with the global patent of Eyedeal Company – cross-linked polyolefin material. This intraocular lens has more ideal biological, mechanical and optical properties than internationally renowned brand products, and can bring a more perfect visual experience to patients around the world.

It is understood that under the current situation that the domestic foldable intraocular lens is monopolized by international giants and the domestic share is extremely limited, Eyedeal is led by the world’s top academicians and senior experts at home and abroad. The research and development team composed of clinical and other multidisciplinary experts has successfully developed two series of intraocular lenses, Eyedeal® and Eyenable® over seven years. As a high-tech enterprise focusing on R&D and production of ophthalmic medical devices with intraocular lenses as the core, Eyedele actively explores the field of ophthalmology and is committed to contributing to human visual health.

Currently, Eyedeal takes the lead in undertaking China’s National Key R&D Programmes and has been selected for the Special Review Procedure for Innovative Medical Devices of the Inspection Center of State Food and Drug Administration, and has established scientific research platforms such as academician expert workstations, engineering research centers, and post-doctoral innovation bases. At the same time, the company is also actively exploring the wide application of new patented materials in the field of other implantable medical devices. As an industry-leading ophthalmic medical device enterprise, the company will continue to provide ideal and perfect products and services to global customers.